Protalix Biotherapeutics Inc (PLX) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $2.72 (+0.74%), Market cap $0.16B, P/E ratio 10.58, 52-week low–high $1.35 ~ $3.15.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreeme
Financial statements, price targets, institutional (13F) holdings and related news for Protalix Biotherapeutics Inc are updated in real time on BlackAll Trade.
Protalix Biotherapeutics Inc trades at $2.72 (+0.74%). Real-time quotes and charts are available on BlackAll Trade.
Protalix Biotherapeutics Inc has a market cap of about $0.16B. Its P/E ratio is 10.58.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based p